A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma.

摘要: Chemotherapy options for esophagogastric adenocarcinoma remain limited. Irinotecan has demonstrated broad activity in a variety of epithelial malignancies. Forty-six patients with previously untreated, measurable, unresectable, or metastatic were enrolled. Patients received irinotecan (125 mg/m2intravenously over 90 min weekly) 4 consecutive weeks followed by 2-week rest. Forty-three at least one treatment and evaluable response toxicity. One complete five partial responses observed, an overall rate 14% (95% CI, 4–24%). Median survival all 43 was 6.4 months 4.6–8.2 months). Grade 3 to toxicity included 10 (23%) neutropenia, 13 (30%) late diarrhea, 6 (14%) vomiting, fatigue. We conclude that although single-agent is active agent adenocarcinoma, the schedule utilized this trial associated moderate When used as single-agent, triweekly may be preferable patient population.